SALT LAKE CITY, UT -- (Marketwired) -- 06/09/14 -- Q Therapeutics, Inc., an emerging biotechnology company developing innovative cell therapy products for the treatment of debilitating diseases of the central nervous system, today announced that the Company has been invited to present at the National Investment Banking Association's (NIBA) 131st Investment Conference to be held in New York on June 16-18, 2014.
NIBA is a national not-for-profit trade association of regional and independent brokerages, investment banking firms, institutional investors and related capital market service providers. Since its inception, NIBA member firms have successfully completed over 1000 equity offerings totaling approximately $10 billion in new capital for America's finest emerging growth companies. The member firms of NIBA represent over 8800 registered representatives with an estimated $78 billion in assets under management, and are responsible for 90% of all Initial Public Offerings under $20 million.
NIBA conferences provide a venue for invited companies to share meaningful insight into their business operations, short and long-term growth strategies and industry vision, give its members the opportunity to exchange ideas and information, evaluate presentations made by public and private companies seeking capital or exposure to the investor community.
EVENT AT A GLANCE
Steve Borst - CFO and Vice President, Corporate Development
June 16-18, 2014
The Roosevelt Hotel
45 E. 45th Street
New York, New York
About Q Therapeutics, Inc.
Headquartered in Salt Lake City, Utah, Q Therapeutics, Inc. is a fully reporting, non-trading company engaged in developing adult stem cell therapies to treat debilitating diseases of the central nervous system. The Company's first product, Q-Cells®, is a cell-based therapeutic intended to restore or preserve normal activity of neurons by providing essential support functions that occur in healthy central nervous system tissues. Q-Cells may be applicable to a wide range of central nervous system diseases, including demyelinating conditions such as multiple sclerosis, transverse myelitis, cerebral palsy and stroke; as well as other neurodegenerative diseases and injuries, such as ALS (Lou Gehrig's disease), Huntington's disease, spinal cord injury, traumatic brain injury, Parkinson's disease and Alzheimer's disease. Q Therapeutics' initial clinical target is ALS, with a first IND submission expected in 2014. The Company's proprietary product pipeline also encompasses neural cell products derived from induced pluripotent stem cells (iPSC). For more information, visit www.qthera.com.